This the difference between the MD and the scientist. The market is neither of those. There is a data problem, management will decide how to proceed and they are not going to throw the baby out with the bath water. It is unlikely we will ever know the source of the discrepancy as they go into arse covering mode (not the truth anyhow). The way out is to proceed with phase 3, present accurate positive results and never discuss phase 2 again. In the mean time other results will come from (hopefully) better managed trials and all will be good with the world. Those who truly believe that this is not a trial mismanagement issue but that the product has failed, should already be out the door. DYOR.
BOT Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
(20min delay)